M
Mari Asada
Researcher at Takeda Pharmaceutical Company
Publications - 8
Citations - 2095
Mari Asada is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Receptor & Chemokine. The author has an hindex of 6, co-authored 8 publications receiving 1961 citations.
Papers
More filters
Journal ArticleDOI
Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor.
Tetsuya Ohtaki,Yasushi Shintani,Susumu Honda,Hirokazu Matsumoto,Akira Hori,Kimiko Kanehashi,Yasuko Terao,Satoshi Kumano,Yoshihiro Takatsu,Yasushi Masuda,Yoshihiro Ishibashi,Takuya Watanabe,Mari Asada,Takao Yamada,Masato Suenaga,Chieko Kitada,Satoshi Usuki,Tsutomu Kurokawa,Haruo Onda,Osamu Nishimura,Masahiko Fujino +20 more
TL;DR: It is shown that KiSS-1 encodes a carboxy-terminally amidated peptide with 54 amino-acid residues, which is isolated from human placenta as the endogenous ligand of an orphan G-protein-coupled receptor (hOT7T175) and named ‘metastin’.
Journal ArticleDOI
New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals.
Shuji Hinuma,Yasushi Shintani,Shoji Fukusumi,Norio Iijima,Yoshio Matsumoto,Masaki Hosoya,Ryo Fujii,Takuya Watanabe,Kuniko Kikuchi,Yasuko Terao,Takahiko Yano,Takanori Yamamoto,Yuji Kawamata,Yugo Habata,Mari Asada,Chieko Kitada,Tsutomu Kurokawa,Haruo Onda,Osamu Nishimura,Masaki Tanaka,Yasuhiko Ibata,Masahiko Fujino +21 more
TL;DR: In this paper, the identification of a human gene that encodes at least three RFamide-related peptides, hRFRP-1-3, has been reported.
Journal ArticleDOI
Metastin suppresses the motility and growth of CHO cells transfected with its receptor.
Akira Hori,Susumu Honda,Mari Asada,Tetsuya Ohtaki,Katsuaki Oda,Takuya Watanabe,Yasushi Shintani,Takao Yamada,Masato Suenaga,Chieko Kitada,Haruo Onda,Tsutomu Kurokawa,Osamu Nishimura,Masahiko Fujino +13 more
TL;DR: The results indicate that metastin is a potent inhibitor of cell motility, leading to suppression of cell growth and antimetastatic activity, and suggest that low molecular chemical compounds could replace its activity as a novel antimetastsatic agent.
Journal ArticleDOI
Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
Daisuke Nakata,Tsuneo Masaki,Akira Tanaka,Mie Yoshimatsu,Yumiko Akinaga,Mari Asada,Reiko Sasada,Michiyasu Takeyama,Kazuhiro Miwa,Tatsuya Watanabe,Masami Kusaka +10 more
TL;DR: It is demonstrated that TAK-385 acts as an antagonist for human GnRH receptor in vivo and daily oral administration potently, continuously and reversibly suppresses the hypothalamic-pituitary-gonadal axis.
Journal ArticleDOI
Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice.
Shuntarou Tsuchiya,Yuichiro Amano,Osamu Isono,Mayumi Imai,Fumi Shimizu,Mari Asada,Shigemitsu Imai,Ayako Harada,Yoshitaka Yasuhara,Ryuichi Tozawa,Hiroshi Nagabukuro +10 more
TL;DR: Low‐density lipoprotein receptor knockout mice fed a modified choline‐deficient and amino acid‐defined (mCDAA) diet show non‐alcoholic steatohepatitis (NASH)‐like pathophysiology.